Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intensive Uric Acid Lowering With RDEA3170 and Febuxostat in Patients With Albuminuria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03118739
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of RDEA3170 and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM)

Condition or disease Intervention/treatment Phase
Hyperuricemia Albuminuria Type 2 Diabetes Drug: RDEA3170 9 mg+Febuxostat 80 mg Drug: Placebo Phase 2

Detailed Description:

Evidence shows independent associations between elevated serum uric acid (sUA) and the risk of hypertension, myocardial infarction (MI), chronic kidney disease (CKD), T2DM, heart failure (HF), and metabolic syndrome, including obesity. Gout is associated with an increased risk of all-cause death, as well as cardiovascular death. The causal relationship between elevated sUA, gout, and these disease outcomes remains to be proven.

RDEA3170 (Verinurad), is a novel Urate Transporter 1 (URAT1) inhibitor in Phase II development. RDEA3170 combined with the xanthine oxidase (XO) inhibitor febuxostat has been shown to lower sUA in patients with recurrent gout in Phase II studies by >80%. The extensive lowering of sUA delivered by the combination presents a unique opportunity to explore whether intensive urate lowering therapy can improve kidney and/or cardiac health.

This study will assess if intensive serum urate lowering therapy, more potent than ever explored before in the chronic out-patient setting, can improve chronic kidney or cardiac function in the study population.

In order to maximize the scientific value of the study and minimize the risk for systemic biases a parallel group, double blind, randomized design will be utilized.

The study will recruit patients with hyperuricemia and presenting with albuminuria.

Hyperuricemic patients are expected to benefit more from urate lowering, and albuminuria at baseline is required, as the primary objective of the study will be to assess changes in albuminuria.

Patients are also required to be diagnosed with T2DM. Patients with T2DM frequently exhibit changes in cardiac function detectable using magnetic resonance imaging (MRI) that represents an early, pre-symptomatic state of HF. By limiting recruitment to patients with T2DM and by performing MRI at baseline and 6 months of therapy, the study will deliver insights into whether or not intensive urate lowering therapy can positively affect not only chronic kidney disease, but also cardiac disease.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, double-dummy, placebo-controlled, parallel, independent groups, repeated measures, multi-center study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: RDEA3170 capsules/matching placebo capsules and febuxostat/matching placebo capsules with randomization code printed on each label
Primary Purpose: Treatment
Official Title: Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Actual Study Start Date : May 18, 2017
Actual Primary Completion Date : August 13, 2018
Actual Study Completion Date : August 13, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RDEA3170 9 mg+Febuxostat 80 mg
Capsule administered orally, once daily for 24 weeks
Drug: RDEA3170 9 mg+Febuxostat 80 mg
Capsule administered orally, once daily for 24 weeks
Other Name: RDEA3170 (Verinurad), Febuxostat(Uloric)

Placebo Comparator: Placebo
Capsule administered orally, once daily for 24 weeks
Drug: Placebo
Capsule administered orally, once daily for 24 weeks




Primary Outcome Measures :
  1. Urinary Albumin to Creatinine Ratio (UACR) after 12 weeks [ Time Frame: From baseline to 12 weeks of treatment ]
    To assess the effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat on albuminuria


Secondary Outcome Measures :
  1. Estimated glomerular filtration rate (eGFR), Cystatin C, creatinine [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess the effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat on kidney function.

  2. Serum uric acid [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess the metabolic effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat

  3. Left ventricular cardiac strain,function and mass, kidney oxygenation [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess the structural and functional effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat on the heart and kidney using magnetic resonance imaging

  4. High sensitivity C-reactive protein and Troponin I [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess the effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat on biomarkers and parameters related to inflammation, and cardiac health

  5. Blood pressure (systolic and diastolic) [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess the effects of intensive uric acid lowering therapy with RDEA3170 and febuxostat on cardiovascular parameters

  6. RDEA3170 plasma concentration at trough [ Time Frame: From baseline up to 24 weeks of treatment ]
    To assess plasma exposure of RDEA3170 in this patient population


Other Outcome Measures:
  1. Rates of adverse events and serious adverse events. Changes in vital signs, physical examinations, and electrocardiograms. Changes in clinical laboratory parameters, including assessment of creatinine, cystatin C, and blood urea nitrogen [ Time Frame: From signing of the informed consent form until 4 weeks after the last dose ]
    To assess the safety and tolerability of intensive uric acid lowering therapy with RDEA3170 and febuxostat



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 150 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Serum Uric Acid ≥6.0 mg/dL
  • eGFR ≥30 mL/min/1.73 m2
  • UACR between 30 mg/g and 3500 mg/g inclusive
  • Diagnosed with T2DM

Exclusion Criteria:

  • Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat) and URAT1 inhibitors (lesinurad, RDEA3170, probenecid, and benzbromarone)
  • Prior history of gout, unless prophylaxis therapy isn't required
  • Patients who are pregnant, lactating, or planning to become pregnant
  • Patients unsuitable or unable to undergo MRI assessment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118739


Locations
Layout table for location information
United States, California
Research Site
Canyon Country, California, United States, 91351
Research Site
Chula Vista, California, United States, 91911
Research Site
Corona, California, United States, 92882
Research Site
Escondido, California, United States, 92025
Research Site
Lakewood, California, United States, 90805
Research Site
Lincoln, California, United States, 95648
Research Site
Los Angeles, California, United States, 90017
Research Site
Los Angeles, California, United States, 90022
Research Site
Los Angeles, California, United States, 90036
Research Site
North Hollywood, California, United States, 91606
Research Site
Oceanside, California, United States, 92056-4510
Research Site
Orange, California, United States, 92868
Research Site
Sacramento, California, United States, 95821
United States, Texas
Research Site
Houston, Texas, United States, 77058
Research Site
Houston, Texas, United States, 77070
Research Site
Pearland, Texas, United States, 77584
Research Site
Sugar Land, Texas, United States, 77478
Research Site
Webster, Texas, United States, 77598
Sponsors and Collaborators
AstraZeneca

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03118739     History of Changes
Other Study ID Numbers: D5495C00007
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data (IPD) will likely not be shared with external collaborators/researchers as this data is planned to be used only for internal decision-making

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Febuxostat
Hyperuricemia
Albuminuria
Pathologic Processes
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Verinurad
Uric Acid
Gout Suppressants
Antirheumatic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs